Navigation Links
Carl Zeiss Continues on Track to Further Growth and Investment
Date:12/13/2012

STUTTGART, Germany, December 13, 2012 /PRNewswire/ --

Strong Portfolio Offsets Cyclical Fluctuations in the Semiconductor Manufacturing Technology Business Group

The Carl Zeiss Group ended fiscal year 2011/12 with a two percent increase in revenue to a total of EUR 4.163 billion (prior year*: EUR 4.084 billion). EBIT totaled EUR 420 million (prior year*: EUR 608 million). "2011/12 was a very successful fiscal year for Carl Zeiss. "We have surpassed the figure we forecast last year: revenue is slightly above the equivalent total in the prior year," said Dr. Michael Kaschke, President and CEO of Carl Zeiss. "What is particularly notable is that our strong portfolio has enabled us to successfully offset the cyclical downturn in the revenue of the Semiconductor Manufacturing Technology business group. This would not have been possible just a few years ago."  

In 2011/12 Carl Zeiss hired 900 new recruits worldwide and increased its investments in research and development by 14 percent. Investments in property, plant and equipment totaled EUR 289 million, allowing the company to modernize and expand its global infrastructure.

*Calculated on a like-for-like basis

More information at http://www.zeiss.de/press

Carl Zeiss

The Carl Zeiss Group is an international leader in the fields of optics and optoelectronics. In fiscal year 2011/12 the company's approx. 24,000 employees generated revenue of about 4.163 billion euros. In the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, Carl Zeiss has contributed to technological progress all over the world for more than 160 years.

The Carl Zeiss Group develops and produces planetariums, eyeglass lenses, camera and cine lenses and binoculars as well as solutions for biomedical research, medical technology and the semiconductor, automotive and mechanical engineering industries. Carl Zeiss is present in over 40 countries around the globe with about 40 production sites, over 50 sales and service locations and approximately 20 research and development centers. Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany.

Press contact
Jörg Nitschke, Carl Zeiss, Konzernkommunikation, Pressesprecher,
Phone +49(0)7364 20-3242, Email: joerg.nitschke@zeiss.com



'/>"/>
SOURCE Carl Zeiss AG
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
2. FUJIFILM Continues To Build 3D Digital Roadmap To Womans Imaging
3. Fujifilm Continues To Grow Its Family Of DR Portables
4. Isis To Receive $1.25 Million Payment As Pfizer Continues Development Of EXC 001
5. Philips continues to improve access to treatment for common cause of death in the U.S. with the delivery of its one-millionth AED
6. PathGroup Unveils a New Look; Continues to Expand Footprint
7. Brainlab Continues to Advance Global Treatment Access and Consistency in Cancer Care Centers
8. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
9. Top OTC Brand deploys Semantelli AETracker to monitor Adverse Events in Facebook
10. Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events
11. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):